Rockefeller Capital Management L.P. purchased a new position in Inogen (NASDAQ:INGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 298,047 shares of the medical technology company’s stock, valued at approximately $36,612,000. Rockefeller Capital Management L.P. owned about 1.40% of Inogen as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. grew its holdings in Inogen by 95.9% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 75,094 shares of the medical technology company’s stock worth $8,942,000 after acquiring an additional 36,759 shares during the last quarter. Swiss National Bank grew its holdings in Inogen by 6.3% in the 4th quarter. Swiss National Bank now owns 30,500 shares of the medical technology company’s stock worth $3,632,000 after acquiring an additional 1,800 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD bought a new stake in Inogen in the 4th quarter worth $1,776,000. Comerica Bank grew its holdings in Inogen by 38.4% in the 4th quarter. Comerica Bank now owns 24,772 shares of the medical technology company’s stock worth $2,995,000 after acquiring an additional 6,870 shares during the last quarter. Finally, Brown Capital Management LLC lifted its position in shares of Inogen by 1.8% in the 4th quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock worth $269,205,000 after purchasing an additional 40,994 shares during the period. 99.40% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Loren L. Mcfarland sold 2,125 shares of Inogen stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $181.44, for a total transaction of $385,560.00. Following the completion of the transaction, the director now directly owns 3,114 shares of the company’s stock, valued at approximately $565,004.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Alison Bauerlein sold 3,192 shares of Inogen stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $125.41, for a total transaction of $400,308.72. Following the transaction, the chief financial officer now directly owns 8,808 shares of the company’s stock, valued at $1,104,611.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,148 shares of company stock valued at $6,778,955. Corporate insiders own 5.29% of the company’s stock.
INGN has been the subject of several research analyst reports. BidaskClub raised shares of Inogen from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $132.00 target price for the company in a research report on Tuesday, February 6th. Piper Jaffray raised shares of Inogen from a “neutral” rating to an “overweight” rating in a research report on Tuesday, February 20th. Finally, Needham & Company LLC raised their target price on shares of Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $178.00.
NASDAQ:INGN opened at $187.76 on Friday. Inogen has a 12 month low of $81.85 and a 12 month high of $188.45. The stock has a market capitalization of $3.98 billion, a PE ratio of 143.33, a P/E/G ratio of 4.75 and a beta of 1.01.
Inogen (NASDAQ:INGN) last posted its earnings results on Monday, April 30th. The medical technology company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.19. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The firm had revenue of $79.05 million during the quarter, compared to analysts’ expectations of $63.86 million. During the same period last year, the company posted $0.27 EPS. The company’s quarterly revenue was up 50.6% compared to the same quarter last year. research analysts predict that Inogen will post 1.76 earnings per share for the current year.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen (NASDAQ:INGN).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.